Lupus Clinical Trials Can Use Organ-Specific Endpoint For Broad Claim – FDA
Executive Summary
FDA's draft guidance on lupus drug development allows for the use of clinical trials on specific organs to support a broader lupus claim
You may also be interested in...
Siren Song Of Lupus Has Left A Legacy Of Failed Trials
The five-decade drought in FDA approvals of lupus therapies – broken by Human Genome Sciences Inc.'s recent launch of Benlysta – featured a steady stream of drug developers that were not dissuaded by the legacy of trial failures and shifting regulatory standards that marked the field, only to join the ranks of clinical failures in lupus.
Siren Song Of Lupus Has Left A Legacy Of Failed Trials
The five-decade drought in FDA approvals of lupus therapies – broken by Human Genome Sciences Inc.'s recent launch of Benlysta – featured a steady stream of drug developers that were not dissuaded by the legacy of trial failures and shifting regulatory standards that marked the field, only to join the ranks of clinical failures in lupus.
Emerging Phase III Data Validate Clinical Trial Design In Lupus
Over a span of little more than a month this summer, the face of clinical trials for lupus drugs changed considerably for the better.